Who is sponsoring NCT04993625?

NCT04993625 is sponsored by Jeong Eon Lee.

What drugs are being tested in NCT04993625?

Interventions in NCT04993625: avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy.

What condition does NCT04993625 study?

NCT04993625 studies Breast Cancer.

Is NCT04993625 still recruiting?

NCT04993625 is currently active, enrolled. Last updated 26 January 2024.

Last reviewed 2024-01-26 · How we verify

NCT04993625: ASLAN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study

Active, enrolled NA Last updated 26 January 2024

What this trial tests

NA trial testing avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy in Breast Cancer in 178 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

27 September 2021

Primary endpoint
31 December 2028

31 December 2028

Quick facts

Lead sponsor	Jeong Eon Lee
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	178
Start date	27 September 2021
Primary completion	31 December 2028
Estimated completion	31 December 2028
Sites	1 location across South Korea

Drugs / interventions tested

avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Jeong Eon Lee

Who can join

Adults 20 to 69, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aims of this study is to evaluate 5 year recurrence free survival when omit sentinel lymph node biopsy after neoadjuvant chemotherapy in triple negative or HER-2 positive breast cancer patients when physical examination expected complete remission. And radiological expected Tumor size ≤ 2cm or non-mass enhancement ≤ 4cm.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial.
Jung JJ, Cheun JH, Kim SY, Koh J, et al · · 2024 · cited 19× · PMID 38433091 · DOI 10.4048/jbc.2023.0265
Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Human Epidermal Growth Factor 2-Positive/Triple-Negative Breast Cancer Patients With Excellent Response.
Ryu JM, Lee H, Han W, Lee HB, et al · · 2024 · cited 7× · PMID 38685868 · DOI 10.4048/jbc.2023.0264
Locoregional Therapy: From Mastectomy to Reconstruction, Targeted Surgery, and Ultra-Hypofractionated Radiotherapy.
Banys-Paluchowski M, Hartmann S, Ditsch N, Krawczyk N, et al · · 2023 · cited 2× · PMID 38130814 · DOI 10.1159/000533748
A Survey of Practice Patterns for Clinical Nodal Staging Prior to Neoadjuvant Chemotherapy in Breast Cancer.
Lee HB, Lee KH, Song SH, Kim K, et al · · 2023 · cited 1× · PMID 37279777 · DOI 10.1093/oncolo/oyad156
Omission of Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: Expanding Evidence in Clinically Node-Negative and Neoadjuvant Therapy Responders.
Grapes A, Young J, Takabe K. · · 2026 · PMID 42147263 · DOI 10.14740/wjon2776
Axillary Surgery in Breast Cancer: Evidence-Based De-escalation Across Upfront and Post-Neoadjuvant Settings.
Park WK, Nam SJ, Kim SW, Yu J, et al · · 2026 · PMID 41612659 · DOI 10.4048/jbc.2025.0290
A Randomized Trial of Sentinel Node Biopsy Omission After Neoadjuvant Systemic Therapy in Clinically Node-Negative or Selected Node-Positive Breast Cancer.
Jung JJ, Kim HJ, Chae BJ, Kim EK, et al · · 2025 · PMID 41311332 · DOI 10.4048/jbc.2025.0157

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Jeong Eon Lee trials

Trials by the same sponsor.

NCT07245316 — Avoiding Surgery in Estrogen Receptor Positive Atypical Ductal Hyperplasia and In-situ Carcinoma Treated With Endocrine · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04993625 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jeong Eon Lee
Last refreshed: 26 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04993625.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing